Median Technologies’ eyonis™ LCS, an AI-powered SaMD for lung cancer screening, has demonstrated strong performance in its REALITY pivotal study. The technology excels in detecting and characterizing cancerous nodules, increasing the accuracy of low-dose computed tomography (LDCT) scans.
By improving the precision of LDCT, eyonis™ LCS has the potential to significantly enhance early detection and boost survival rates for lung cancer patients. The current five-year survival rate for all lung cancer cases is a mere 18.6%, largely due to late-stage diagnoses. However, early detection in Stage 1 can lead to an 80% survival rate after 20 years.
Furthermore, eyonis™ LCS saves lives and prevents unnecessary medical procedures for healthy patients. This reduces anxiety for patients and minimizes healthcare expenses. The technology holds immense potential to revolutionize lung cancer screening and detection, especially given the increasing focus on early detection initiatives worldwide.
The U.S. Preventive Services Task Force (USPSTF) recommends lung cancer screening for adults aged 50 to 80 with a significant smoking history. In the US alone, this population numbers 14.5 million, creating a substantial market opportunity for eyonis™ LCS. The addressable market is valued at over $9 billion annually, with a potential reimbursement of $650 per exam.
The exceptional performance of eyonis™ LCS in REALITY bodes well for the upcoming RELIVE pivotal study. Median Technologies anticipates filing for marketing authorizations in H1 2025, paving the way for broader implementation of eyonis™ LCS in both the U.S. and Europe. The technology aims to reduce mortality and transform patient outcomes by improving lung cancer detection accuracy.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Ferry, a computer data scientist, focuses on the latest clinical trial industry news and trends.
